Keyphrases
JC Polyomavirus (JCPyV)
100%
Polyomavirus
100%
Progressive multifocal Leukoencephalopathy
100%
Neutralizing Antibodies
50%
CNS Disorders
50%
Brain Diseases
33%
T Cells
33%
Ependyma
33%
Mouse Polyomavirus
33%
Virus
33%
Immunosuppressive Agents
33%
Antibody Escape
33%
Multiple Sclerosis Treatment
16%
Innate Immunity
16%
Tropism
16%
Therapeutic Potential
16%
Autoimmune Disease
16%
Life-threatening Complications
16%
Interleukin-21 (IL-21)
16%
High Mortality
16%
Reconstruction Approach
16%
Virus-neutralizing Antibody
16%
Inflammatory Disorders
16%
High Affinity
16%
Virus-host Interactions
16%
Next-generation Sequencing
16%
Protein mutations
16%
Host Model
16%
T Cell Depletion
16%
Demyelinating
16%
Mouse Brain
16%
Virus Variants
16%
CD-8
16%
Inflammatory Response
16%
Human Pathogens
16%
Natural Virus
16%
High Incidence
16%
Image Reconstruction
16%
Tissue Culture
16%
Neuropathology
16%
Cryo-EM Images
16%
Malignancy
16%
Persistent Infection
16%
Early Events
16%
In Vivo Evaluation
16%
Drug Withdrawal
16%
Brain Parenchyma
16%
CNS Infection
16%
Escape Mechanism
16%
Natalizumab
16%
VP1 Capsid Protein
16%
Immunology and Microbiology
Polyomavirus
100%
Neutralizing Antibody
80%
Virus
80%
Murine Polyomavirus
40%
T Cell
40%
Ependyma
40%
Natalizumab
40%
Parenchyma
20%
Next Generation Sequencing
20%
Multiple Sclerosis
20%
STAT1
20%
Cryo-Electron Microscopy
20%
Human Pathogen
20%
Clinically Isolated Syndrome
20%
Inflammatory Disorder
20%
CD8
20%
Innate Immune System
20%
Capsid
20%
Biological Product
20%
Tissue Culture
20%
Drug Withdrawal
20%
T Cell Deficiency
20%
Neuroscience
Polyomavirus
100%
Progressive Multifocal Leukoencephalopathy
85%
Neutralizing Antibody
57%
T Cell
42%
Ependyma
28%
In Vivo
28%
Natalizumab
28%
Multiple Sclerosis
14%
CD8
14%
Protein VP1
14%
Parenchyma
14%
Demyelinating Disease
14%
Drug Withdrawal
14%
Cryo-Electron Microscopy
14%
STAT1
14%
Mouse Brain
14%